9月12日：Exploit clinical benefit of biomaterials for orthopedic therapies: challenge and opportunities
报告人：Prof. Chaozong Liu
John Scale Centre for Biomedical Engineering
Division of Surgery and Interventional Science
University College London
The Royal National Orthopaedic Hospital, Stanmore
UCL is one of the global top research intensive universities on a research output dominated by its Biomedical and Engineering Faculties. UCL’s contribution to the programme will be led by Institute of Orthopaedics and Musculoskeletal Science (IOMS) which is an internationally leading Centre of research and postgraduate training. Its research straddling medical and bio-medical engineering applications. It has reputation and track record for innovative translation research, and has established expertise in technology transferring such as Stanmore Implant Worldwide. IOMS and staffs from the Royal National Orthopaedic Hospital lead units of major importance in clinical care and are at the cutting edge of research and development in implant innovation, cell-engineering and rapid fabrication of tissues. These have applications in musculoskeletal system and vascular regeneration. IOMS provides a unique environment for collaboration between scientists, engineers, and clinicians in an Academic Health Sciences Centre model, in order to speed up the development of improvements in patient care.
E-mail: Chaozong.Liu@ucl.ac.uk; Tel: 020 8954 9427
Dr Chaozong Liu is an associate professor in Biomedical Engineering, the programme leader of MSc in Musculoskeletal Science, and the group leader of UCL Biomaterials & Osteochondral Tissue Engineering within the Division of Surgery & Interventional Science University College London. He has several years’ experience of biomaterials processing and development of medical devices.
Dr Liu’s current research is directed toward the development of enhanced medical devices for treating musculoskeletal disorders, tissue repair and regeneration. This is a growing area of interest at UCL Surgical & Interventional Science. His research in this area is supported by ARUK, Innovate UK, Horizon2020, EPSRC MeDe Innovation Centre and RoseTree Trusts, and from Fitzpatrick Referrals Ltd. He has developed a new osteochondral scaffold technology that is likely to have a strong potential in regeneration of bone and cartilage for early intervention of osteoarthritis. Preclinical study has demonstrated that the new osteochondral scaffold has the strength needed to bear the physical load of the joints and its patented biomedical structure encourages consistent cartilage fill. A glimpse of how this scaffold will perform has been given, with promising results, by Professor Noel Fitzpatrick of the Channel 4 TV series Supervet, where it was implanted in a pet dog shoulder to treat a large osteochondral defect. The recent awards from Innovate UK-MoST and EU HORIZON2020 have significantly boosted his research in this field.